GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Zogenix Inc (NAS:ZGNX) » Definitions » Revenue

Zogenix (Zogenix) Revenue : $81.69 Mil (TTM As of Dec. 2021)


View and export this data going back to 2010. Start your Free Trial

What is Zogenix Revenue?

Zogenix's revenue for the three months ended in Dec. 2021 was $26.61 Mil. Its revenue for the trailing twelve months (TTM) ended in Dec. 2021 was $81.69 Mil. Zogenix's Revenue per Share for the three months ended in Dec. 2021 was $0.48. Its Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2021 was $1.46.

During the past 12 months, the average Revenue per Share Growth Rate of Zogenix was 475.60% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get other companies' revenue growth rate using Revenue per Share data.

During the past 13 years, Zogenix's highest 3-Year average Revenue per Share Growth Rate was -11.00% per year. The lowest was 0.00% per year. And the median was -39.10% per year.


Zogenix Revenue Historical Data

The historical data trend for Zogenix's Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Zogenix Revenue Chart

Zogenix Annual Data
Trend Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21
Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only 9.82 - 3.65 13.64 81.69

Zogenix Quarterly Data
Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21
Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 8.50 13.68 18.79 22.61 26.61

Competitive Comparison of Zogenix's Revenue

For the Biotechnology subindustry, Zogenix's Revenue, along with its competitors' market caps and Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Zogenix's Revenue Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Zogenix's Revenue distribution charts can be found below:

* The bar in red indicates where Zogenix's Revenue falls into.



Zogenix Revenue Calculation

Also referred as sales, revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top.

Revenue for the trailing twelve months (TTM) ended in Dec. 2021 adds up the quarterly data reported by the company within the most recent 12 months, which was $81.69 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Zogenix  (NAS:ZGNX) Revenue Explanation

In ranking the predictability, companies with more consistent revenue and earnings growth are ranked high with predictability.

Peter Lynch categorized companies according to their revenue growth:


Slow Grower: Inflation < 10-Year Revenue Growth Rate < 10%:
Stalwart: 10% < 10-Year Revenue Growth Rate < 20%:
Fast Grower: 10-Year Revenue Growth Rate > 20%:

His favorite companies are stalwart, those growing between 10-20% a year.

Companies in cyclical industries may see their revenue fluctuate wildly in good years and bad years.


Be Aware

Revenue can be manipulated by changing the way how revenue is booked. Companies may book sales before the payment is received, or before the revenue is fully earned. These will be added to balance sheet items such as account payable or account receivables.


Zogenix Revenue Related Terms

Thank you for viewing the detailed overview of Zogenix's Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Zogenix (Zogenix) Business Description

Traded in Other Exchanges
N/A
Address
5959 Horton Street, Suite 500, Emeryville, CA, USA, 94608
Zogenix Inc is engaged in developing and commercializing therapeutic solutions for people living with serious and life-threatening rare CNS disorders and medical conditions. Its product candidate includes ZX008, low-dose fenfluramine for the treatment of Dravet syndrome, LGS, and potentially other rare and catastrophic epilepsy disorders.
Executives
Erle T Mast director C/O SPIROS DEVELOPMENT CORP II INC, 7475 LUSK BLVD, SAN DIEGO CA 92121
Renee P Tannenbaum director 9220 KIRBY DRIVE, SUITE 500, HOUSTON TX 77054
Cam L Garner director PO BOX 675866, RANCHO SANTE FE CA 92067
Caroline M Loewy director 300 ELLIOTT AVE WEST, SUITE 500, SEATTLE WA 98119-4114
Denelle J Waynick director C/O MYOKARDIA, INC. 1000 SIERRA POINT PARKWAY BRISBANE CA 94005
Mary E. Stutts director C/O ZOGENIX, INC. 5959 HORTON STREET EMERYVILLE CA 94608
Ashish M Sagrolikar officer: EVP & CHIEF COMMERCIAL OFFICER C/O ZOGENIX, INC. 5858 HORTON STREET, #455 EMERYVILLE CA 94608
Gail M Farfel officer: EVP/Chief Development Officer 142 TEMPLE STREET, SUITE 205, NEW HAVEN CT 06510
Bradley S. Galer officer: EVP/Chief Medical Officer C/O ZOGENIX, INC. 12400 HIGH BLUFF DR., SUITE 650 SAN DIEGO CA 92130
Stephen J Farr director, officer: President and CEO [email protected] EMERYVILLE CA 94608
Mark C Wiggins director 12671 HIGH BLUFF DRIVE SUITE 200, SAN DIEGO CA 92130
Louis C Bock director C/O BANKAMERICA VENTURES, 950 TOWER LANE STE 700, FOSTER CITY CA 94404
James B Breitmeyer director
Shawnte Mitchell officer: EVP, GC and Secretary 5959 HORTON STREET, SUITE 500, EMERYVILLE CA 94608
Michael P Smith officer: EVP, CFO, Treasurer & Sec. 887 GREAT NORTHERN WAY VANCOUVER A1 V5T 4T5

Zogenix (Zogenix) Headlines

From GuruFocus

Zogenix Reports Granting of Inducement Awards

By GlobeNewswire GlobeNewswire 08-16-2021

Zogenix Reports Granting of Inducement Awards

By GuruFocusNews GuruFocusNews 11-17-2021

Zogenix Reports Granting of Inducement Awards

By GlobeNewswire GlobeNewswire 09-16-2021